Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase III trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 3, 2015-03 ,pp. : 309-312

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacological characterization of ZYDPLA1, a novel long‐acting dipeptidyl peptidase‐4 inhibitor 一种新型的长效二肽基肽酶‐4抑制剂ZYDPLA1的药理特性

By  

JOURNAL OF DIABETES, Vol. 7, Iss. 5, 2015-09 ,pp. : 708-717

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pemphigus vulgaris developing after 6‐month treatment with a dipeptidyl peptidase‐4 inhibitor: A case report

By  

THE JOURNAL OF DERMATOLOGY, Vol. 45, Iss. 2, 2018-02 ,pp. : e39-e40

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects

By He Yan-Ling   Sabo Ron   Riviere Gilles-Jacques   Sunkara Gangadhar   Leon Selene   Ligueros-Saylan Monica   Rosenberg Mitchell   Dole William P.   Howard Dan  

Current Medical Research and Opinion, Vol. 23, Iss. 5, 2007-05 ,pp. : 1131-1138

Informa Healthcare

Access to resources Recommend Favorite

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes

By Herman Gary A.   Bergman Arthur   Yi Bingming   Kipnes Mark    

Current Medical Research and Opinion, Vol. 22, Iss. 10, 2006-10 ,pp. : 1939-1947

Informa Healthcare

Access to resources Recommend Favorite